Skip to main content
Clinical Trials/NCT03755856
NCT03755856
Unknown
Not Applicable

A Survivorship Project to UnerstAnd and to impRove Long-Term Outcomes for Acute Myeloid Leukemia Patients (SPARTA): the Sparta Platform

Gruppo Italiano Malattie EMatologiche dell'Adulto39 sites in 8 countries343 target enrollmentStarted: May 16, 2019Last updated:

Overview

Phase
Not Applicable
Enrollment
343
Locations
39
Primary Endpoint
Number of differences in SF-36 scores

Overview

Brief Summary

This international observational study aims at examining the patterns of health-related quality of life differences between long-term acute myeloid leukemia patients and their healthy peers from the general population.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of all subtypes of de novo AML, according to WHO criteria (at least 20% blasts in the bone marrow), except acute promyelocytic leukemia (APL).
  • Age at AML diagnosis ≥ 18 years,
  • Date of AML diagnosis at least 5 years before study enrollment,
  • AML-free status at study enrollment,
  • Written informed consent provided.

Exclusion Criteria

  • Major cognitive deficit or psychiatric problems hampering a self-reported evaluation,
  • Not speaking and reading the language of the participating country,
  • More than 75 years at the time of study enrollment,
  • Receiving any active treatment for AML at the time of study enrollment.

Outcomes

Primary Outcomes

Number of differences in SF-36 scores

Time Frame: At enrollment

The Role Physical scores of AML survivors will be compared to that in the general population as assessed by SF-36 questionnaire. Comparisons will be performed on age-sex matched pairs of AML patients and healthy subjects from the general population.

Secondary Outcomes

  • Outcomes from SF-36 questionnaire will be described and compared between AML patients from RCTs vs non RCTs.(At enrollment)
  • Outcomes from SCQ questionnaire will be described and compared between AML patients from RCTs vs non RCTs.(At enrollment)
  • Outcomes from EORTC QLQ-C30 questionnaire will be described and compared between AML patients from RCTs vs non RCTs.(At enrollment)
  • QoL profiles of AML survivors will be compared with those in the general population also as assessed by EORTC QLQ-C30 questionnaire.(At enrollment)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (39)

Loading locations...

Similar Trials